ReviewClinical reviews in allergy & immunology2025
Immune and Non-immune Interactions in the Pathogenesis of Androgenetic Alopecia.
Review in Clinical reviews in allergy & immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Scalp Microbiome Alterations in Androgenetic Alopecia: Patterns and Emerging Mechanistic Insights.International journal of dermatology · 2026Review
- Single-Cell Profiling Reveals a Protective WNT5A-ATF3-FOSB Signaling Axis in Hair Follicle Stem Cells During Androgenetic Alopecia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Taurine-based Active Pharmaceutical Ingredient Ionic Liquids Modulate the Perifollicular Microenvironment for Androgenic Alopecia Treatment.Advanced healthcare materials · 2026Article
- ACOD1 deficiency promotes DDX1 methylation-mediated mitochondrial dysfunction and dermal papilla cell senescence in androgenetic alopecia.BMC medicine · 2026Article
- Exploring the Potential Role of Hydroxytyrosol in Androgenetic Alopecia: An Integrated Bioinformatics and Molecular Simulation Study.International journal of molecular sciences · 2026Article
- Skin manifestations of hyperandrogenism: an update.Hormones (Athens, Greece) · 2026Review
- Dyslipidemia, hormonal profiles, and sleep characteristics in men with androgenetic alopecia: an analysis based on data from the EPISONO study.Hormones (Athens, Greece) · 2026Article
- The Possible Role of Antibodies in Alopecia: A Narrative Review.Antibodies (Basel, Switzerland) · 2026Review
- Role of MEG3-miRNAs in immune-inflammatory regulation in age-dependent wool follicle remodeling in Tan sheep.BMC genomics · 2026Article
- Nanotechnology-Based Strategies for Hair Regeneration: Mechanistic Insights and Translational Perspectives for Androgenetic Alopecia.Biomedicines · 2026Review
- Biomedical Technologies for Androgenic Alopecia Treatment: Advance, Mechanism and Future Direction.Research (Washington, D.C.) · 2026Review
- Progress in the Application of Exosomes in Androgenetic Alopecia: Focusing on Molecular Mechanisms.International journal of nanomedicine · 2026Review
- Engineered Exosomes Co-Delivering EGF and FGF Ameliorate Androgenetic Alopecia in a Mouse Model.International journal of nanomedicine · 2026Article
- Comparative efficacy of oral dutasteride and low-, medium-, and high-dose oral minoxidil: a six-month prospective trichoscopic and clinical study.Frontiers in medicine · 2026Article
- Clinical characteristics and factors associated with different BASP subtypes of androgenetic alopecia.Frontiers in medicine · 2026Article
- The Roles of EDA2R in Ageing and Disease.Aging cell · 2025Review
- Combined Use of Aqueous Extracts and Polysaccharides from Angelica sinensis and Platycladus orientalis Treats Androgenetic Alopecia.Plant foods for human nutrition (Dordrecht, Netherlands) · 2025Article
- Novel Strategies for Androgenetic Alopecia Therapy: Integrating Multifunctional Plant Extracts with Nanotechnology for Advanced Cutaneous Drug Delivery.Pharmaceutics · 2025Review
- Advances in Transdermal Delivery Systems for Treating Androgenetic Alopecia.Pharmaceutics · 2025Review
- Androgenetic Alopecia: An Update on Pathogenesis and Pharmacological Treatment.Drug design, development and therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Androgenetic alopecia (AGA), a leading cause of progressive hair loss, affects up to 50% of males aged 50 years, causing significant psychological burden. Current treatments, such as anti-androgen drugs and minoxidil, show heterogeneous effects, even with long-term application. Meanwhile, the large-scale adoption of other adjuvant therapies has been slow, partly due to insufficient mechanistic evidence. A major barrier to developing better treatment for AGA is the incomplete understanding of its pathogenesis. The predominant academic consensus is that AGA is caused by abnormal expression of androgens and their receptors in individuals with a genetic predisposition. Emerging evidence suggests the contributing role of factors such as immune responses, oxidative stress, and microbiome changes, which were not previously given due consideration. Immune-mediated inflammation and oxidative stress disrupt hair follicles' function and damage the perifollicular niche, while scalp dysbiosis influences local metabolism and destabilizes the local microenvironment. These interconnected mechanisms collectively contribute to AGA pathogenesis. These additional aspects enhance our current understanding and confound the conventional paradigm, bridging the gap in developing holistic solutions for AGA. In this review, we gather existing evidence to discuss various etiopathogenetic factors involved in AGA and their possible interconnections, aiming to lay the groundwork for the future identification of therapeutic targets and drug development. Additionally, we summarize the advantages and disadvantages of AGA research models, ranging from cells and tissues to animals, to provide a solid basis for more effective mechanistic studies.
Indexed as
Identifiers
40024940What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.